Equities

Genincode PLC

GENI:LSE

Genincode PLC

Health CareMedical Equipment and Services
  • Price (GBX)5.50
  • Today's Change-0.125 / -2.22%
  • Shares traded451.50k
  • 1 Year change-46.34%
  • Beta--
Data delayed at least 20 minutes, as of Sep 27 2024 14:52 BST.
More ▼

Profile data is unavailable for this security.

About the company

GENinCode Plc is a United Kingdom-based polygenics company focused on the prevention of cardiovascular disease and ovarian cancer. The Company operates business units in the United Kingdom, Europe through GENinCode S.L.U, and in the United States through GENinCode U.S. Inc. Its predictive technology provides patients and physicians with preventative care and treatment strategies. GENinCode CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict cardiovascular disease. The Company's core products include Cardio inCode - Score and Check - Coronary predictive/risk assessment; Thrombo inCode - Hematology, Recurrent Pregnancy Loss and Oncology, Thrombosis (blood clots) predictive/risk assessment; Lipid inCode - Familial Hypercholesterolemia Diagnosis and risk stratification, and SudD inCode - Hereditary Cardiomiopathies diagnosis, Risk assessment for sudden cardiac events.

  • Revenue in GBP (TTM)2.16m
  • Net income in GBP-7.02m
  • Incorporated2018
  • Employees36.00
More ▼

Peer analysis

CompanyRevenue (TTM)Net income (TTM)Market capEmployeesMarket Cap /
Employees
Image Scan Holdings Plc2.56m-11.06k2.81m14.002.81m14.00
Aptamer Group PLC1.04m-7.01m4.51m54.004.51m54.00
Myhealthchecked PLC10.98m-159.00k5.72m10.005.72m10.00
Surgical Innovations Group Plc12.01m-509.00k5.93m101.005.93m101.00
Feedback plc886.00k-3.49m6.20m24.006.20m24.00
Rua Life Sciences PLC2.19m-1.44m6.98m33.006.98m33.00
Cambridge Nutritional Sciences PLC9.77m-328.00k8.03m94.008.03m94.00
Proteome Sciences plc4.04m-4.08m8.69m35.008.69m35.00
Genedrive PLC272.00k-5.00m11.02m43.0011.02m43.00
Genincode PLC2.16m-7.02m11.68m36.0011.68m36.00
Renalytix PLC2.54m-34.56m15.47m80.0015.47m80.00
Ondine Biomedical Inc665.76k-7.98m15.93m43.0015.93m43.00
Verici DX PLC3.24m-3.60m16.06m19.0016.06m19.00
Data as of Sep 27 2024. Currency figures normalised to Genincode PLC's reporting currency: UK Pound GBX

Institutional shareholders

31.83%Per cent of shares held by top holders
HolderShares% Held
Octopus Investments Ltd.as of 27 Jun 202431.26m17.66%
Downing LLPas of 31 Dec 202310.64m6.01%
Maitland Asset Management (Pty) Ltd.as of 07 Feb 20248.47m4.78%
Chelverton Asset Management Ltd.as of 31 Dec 20235.65m3.20%
Santander Private Banking Gestion SA SGIICas of 30 Jun 2024315.50k0.18%
West Yorkshire Pension Fundas of 31 Mar 20240.000.00%
More ▼
Data from 30 Jun 2023 - 30 Aug 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.